All, I am in London, so my hours are a little off from what they normally are, but I see there has been some excellent discussion on this topic. I know there has been a lot of discussion about what happens if we can’t all agree on a topic and the application of what has been called the “Neuman Rule” (which by the way is flattering 😊). But that said, I want us to try an exercise of thinking about this issue from a fresh lens and trying to see if there are any scenarios in which a so-called closed generic could be applied for and accepted. IF we keep reverting to the conversation of what will be the situation if we don’t agree, then that may serve as an impediment to all of us working to think about this issue in a collaborative creative way. Yes, we will eventually have to deal with that important question for this and some other issues. I am not denying that. But the optimistic side of me still believes firmly in the multi-stakeholder model and that if we put our collective minds together on this and other solutions, we may reach some surprising and satisfying results. So, I want to again put up the GAC Advice because I think it is important here: “For strings representing generic terms, exclusive registry access should serve a public interest goal." The GAC did not advise an outright ban. Nor did they define the criteria for what they considered would “serve a public interest goal.” The Working Group in its Initial Report provided some potential options for public comment. Alan has presented a additional proposal (Thank you Alan!). The main question for next call is for those that have been advocating the complete ban is whether or not there is any scenario that they can envision an application for excusive registry access could “serve a public interest goal. If the answer is no from a substantial amount of people, then we will end the discussions. If the answer is yes, then we can continue the discussions and yes, discuss this in a face to face. But if the answer is no, then having a face to face meeting on this will not be productive. The answer to the above question should in no way depend on what the status quo was or is. ********************************************** DISCLAIMER: There are some the believe I (or Cheryl) have an interest in seeing this go in one direction or another. But the truth is that the leadership does not. My company may have a position, but they understand that I am not acting on behalf of my company here and in fact, I have not been a part of the comments they have been or will be developing. Jeff Neuman Senior Vice President Com Laude | Valideus 1751 Pinnacle Drive Suite 600, McLean VA 22102, USA M: +1.202.549.5079 D: +1.703.635.7514 E: jeff.neuman@comlaude.com<mailto:jeff.neuman@comlaude.com> www.comlaude.com<http://www.comlaude.com/> [cid:image002.jpg@01D5E709.93238C40] ________________________________ The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that the Com Laude Group does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 06181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176, having its registered office at 33 Melville Street, Edinburgh, Lothian, EH3 7JF Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, headquartered at 1751 Pinnacle Drive, Suite 600, McLean, VA 22102, USA; Com Laude (Japan) Corporation, a company registered in Japan having its registered office at Suite 319,1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan. For further information see www.comlaude.com<https://comlaude.com>
